By: Zara Nwosu
Denmark-based Novo Nordisk has reached an agreement to acquire Cardior Pharmaceuticals for 1.025 billion Euros ($1.1 billion). The deal includes an upfront payment and additional payments if predetermined commercial and development milestones are met.